Category Archives: Inside BIO Industry Analysis

Congress, Media Focused on Biotech Food Labeling

food label

Media coverage of the biotech food labeling debate is at a fever pitch as the Safe and Accurate Food Labeling Act (H.R. 1599) is poised to see action on the floor of the House of Representatives this week. Among the highlights: Charles Conner, former United States Deputy Secretary of Agriculture and current president and CEO of the National Council of Farmer Cooperatives wrote an op-ed in RollCall: GMOs have been around for decades, helping farmers Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

The Bio Report: What a Decade of Investment Tells Us About the Health of Biotech

Emerging Therapeutic Company Investment and Deal Trends

In this podcast, The Bio Report’s Daniel Levine interviews BIO’s Dave Thomas on the recent release of a new BIO Industry Analysis report – Emerging Therapeutic Company Investment and Deal Trends – highlighting ten years (2005-2014) of biotechnology funding and deal making across five areas: venture capital, IPOs, follow-on public offerings, licensing, and acquisitions. The report also offers a first-time look at the degree of collaboration across the industry’s clinical pipeline. Some of the key findings Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

State of the Industry for Emerging Therapeutic Companies

Emerging Therapeutic Company Investment and Deal Trends

Emerging therapeutic companies are at their strongest point in a decade. In our new report on investment and deal trends, the BIO Industry Analysis team shows how this segment within the biotech industry has been faring over the last 10 years. The annual aggregate totals show that for almost every funding or deal activity analyzed, 2014 was the peak year of the last decade. A strong public market, a revitalized private funding environment, and a Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,

Maximize Your Savings Potential During BIO International Convention

BIO-Business-Solutions-Tagline

$161,000,000 That’s how much BIO saved life science companies in aggregate on their 2014 purchases of products and services. More than 2,800 companies nationwide participate in the industry’s largest cost savings program known as BIO Business Solutions®, by taking advantage of the program’s preferential pricing and other benefits. Find out how your company can save money and become a partaker by stopping by the Member Services Pavilion at booth #2001 during the convention. BIO’s Member Services Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , ,

13 Days Until BIO 2015: Moneyball: Acing the Big Pharma/Small Biotech Deal

BIO Business Networking

In just a few weeks, thousands of players in the pharma and biotech industry will converge on Philadelphia for BIO 2015 seeking knowledge, insight and, for many, the ultimate goal – new partnerships. Collaboration is often the key to success for emerging biotech companies and big pharma alike as it can open the door to new markets, influencers and revenue streams. In oncology, deals between established pharmaceutical companies and early-stage biotechs are especially relevant and Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , ,